Cytek Biosciences, INC Form 4 insider transactions

Ilan Feuchtwang, Chief Legal Officer, Secretary of Cytek Biosciences, Inc., reported multiple transactions in common stock on August 10, 2026.

Cytek Biosciences Chief Technology Officer Ming Yan reported a gift of 135,892 shares of common stock.

Director Jack Ball acquired 43,973 shares of Cytek Biosciences common stock through the vesting of restricted stock units.

Director Glenn P. Muir was granted 55,555 restricted stock units and 29,835 stock options by Cytek Biosciences.

Director Richard Chin was granted 33,333 restricted stock units and 18,261 stock options by Cytek Biosciences.

Director Vera Imper acquired common stock through RSU vesting and received new equity grants in Cytek Biosciences.

Director Deborah J. Neff acquired 43,973 shares of Cytek Biosciences common stock through the vesting of restricted stock units.

Director Michael Holder acquired 43,973 shares of Cytek Biosciences through RSU vesting while receiving new equity grants.

Cytek Biosciences director Michael Holder acquired 1,454 shares of common stock through the vesting of restricted stock units.

Cytek Biosciences Director Richard Chin acquired 6,107 shares of common stock through the vesting of restricted stock units.

Chief Technology Officer Yan Ming acquired 22,179 shares of Cytek Biosciences common stock through the vesting of restricted stock units.

SVP of Global Sales and Services Philippe Busque reported the vesting and tax-related withholding of restricted stock units.

Cytek Biosciences CEO Wenbin Jiang acquired 80,062 shares through RSU vesting and withheld 25,542 shares for tax obligations.

Cytek Biosciences CFO William D. McCombe reported the vesting of restricted stock units and subsequent tax-related share withholding.

Chief Legal Officer Valerie Barnett reported the vesting and partial withholding of restricted stock units for tax obligations.

Cytek Biosciences' Chief Technology Officer, Yan Ming, reported gifting 1,176,000 shares of common stock.

Cytek Biosciences Director Richard Chin converted 6,107 Restricted Stock Units into common stock on March 10, 2026, increasing his direct common stock holdings.

Cytek Biosciences' Chief Legal Officer, Valerie Barnett, reported routine equity transactions including RSU vesting, stock option grants, and shares withheld for tax obligations.

Cytek Biosciences' President and CEO, Wenbin Jiang, reported the vesting of restricted stock units and employee stock options, alongside associated tax withholdings.

Cytek Biosciences CFO William D. McCombe reported recent equity transactions, including RSU vesting, tax-related share disposals, and new equity awards.

Cytek Biosciences' Chief Technology Officer, Yan Ming, reported the vesting of restricted stock units, the grant of new equity awards, and associated tax withholdings.

Cytek Biosciences Director Michael Holder converted 2,908 Restricted Stock Units into common stock on March 10, 2026, increasing his direct common stock holdings.

Cytek Biosciences' Chief Technology Officer, Yan Ming, increased direct beneficial ownership of common stock by 15,908 shares following the vesting and conversion of Restricted Stock Units on November 18, 2025.

Philippe Busque, SVP of Global Sales and Services at Cytek Biosciences, reported the vesting of Restricted Stock Units and subsequent sale of shares to cover tax obligations.

Cytek Biosciences' Chief Legal Officer, Valerie Barnett, reported routine vesting of Restricted Stock Units and associated tax-related share dispositions.

Cytek Biosciences' CFO, William D. McCombe, reported the vesting of Restricted Stock Units and subsequent stock transactions, including tax-related dispositions.

Cytek Biosciences' President and CEO, Wenbin Jiang, increased his direct beneficial ownership of common stock through the vesting and exercise of Restricted Stock Units, with some shares withheld for tax obligations.

Cytek Biosciences Director Michael Holder acquired 2,181 shares of common stock through the exercise of Restricted Stock Units on November 18, 2025, increasing his direct beneficial ownership.

Cytek Biosciences Director Richard Chin reported the conversion of 6,107 Restricted Stock Units into common stock on November 18, 2025.

Cytek Biosciences' Chief Technology Officer and Director, Ming Yan, reported the acquisition of shares from Restricted Stock Unit vesting and the sale of shares to cover tax obligations.